Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAI Floxuridine + Systemic Irinotecan for Colorectal Liver Metastases
NCT00063960Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Aug 2003
- Primary completion
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of floxuridine and irinotecan in colorectal cancer (CRC), sponsored by Cancer and Leukemia Group B. Primary endpoints: Toxicity Assessment and Overall Survival at 2 years. Started Aug 2003; status: completed.
02
Drugs
floxuridineirinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00063960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00063960.